ICH M13 [BE/BA News]

posted by ElMaestro  – Belgium?, 2019-11-27 21:42  – Posting: # 20879
Views: 790

Hi Hötzi,

thank you.
It will be interesting to see if they will then harmonize the definition of BE. That little subtle difference between EMA's and FDA's definition makes all the difference between allowing PD to be part of a BE proof, or whether that should rather be called TE with all it entails in relation to the discussion of 10.3's, 10.1/10.2's , 505(b)(2)'s, 505(j)'s and so forth.

I am looking forward to seeing how it pans out.

Elegantly, if this is only about IR SODFs then I guess in all (?) cases PK is the go-to method, so possibly they can avoid discussing the definition altogether. Are there any IR SODF's where it could become tricky? Some of the locally acting anti-diarrheal drugs perhaps or the corticosteroids for Crohn's or Colitis Ulcerosa?

Le tits now.

Best regards,
ElMaestro

Complete thread:

Activity
 Admin contact
20,258 posts in 4,264 threads, 1,400 registered users;
online 12 (0 registered, 12 guests [including 9 identified bots]).
Forum time (Europe/Vienna): 03:47 CET

Science is simply common sense at its best that is,
rigidly accurate in observation, and
merciless to fallacy in logic.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5